Peptide News Digest

Receptor.AI + Sethera Peptide Alliance, Indian Pharma Selloff, Survodutide MASH Phase 2, Merck Q2 Preview

Receptor.AI + Sethera AI-guided polymacrocyclic peptide alliance. Nifty Pharma -2% Monday. Survodutide MASH 83% histological improvement. Merck Q2 Tuesday.

4 stories · Covering industry, clinical-trials

Editor's Note

Monday's peptide news anchors on a fresh AI-guided peptide discovery alliance. Receptor.AI (a US techbio) and Sethera Therapeutics announced Monday August 3, 2026 an integrated discovery collaboration combining Sethera's proprietary polymacrocyclic peptide chemistry (installs 1-6 stable cross-links to generate polymacrocyclic, nested, in-line, and interpeptide structures across large encoded libraries) with Receptor.AI's physics-based modeling, artificial intelligence, and multiparameter optimization. The collaboration targets historically hard-to-drug therapeutic targets that resist small-molecule and antibody approaches. On the market side, Indian pharmaceutical stocks continued the Monday morning selloff following President Trump's Truth Social announcement of the phased generic-drug tariff schedule confirmed Friday August 1 (0% now → 100% August 1 2028 → 200% August 1 2029). Nifty Pharma slumped nearly 2%, making it the worst-performing sectoral index on the National Stock Exchange in early trade; Gland Pharma led losses down 4.54%; Cipla, Sun Pharma, and Dr Reddy's all lost 1-2%. Boehringer Ingelheim's survodutide (BI 456906, dual GLP-1/glucagon receptor agonist) Phase 2 MASH results continue to circulate ahead of Phase 3 readouts expected in late 2026, with 83% of MASH patients achieving histological improvement at 48 weeks. And the peptide-and-obesity Q2 earnings week kicks off Tuesday August 4 with Merck (NYSE: MRK) reporting before market open; analyst attention on Keytruda trajectory, LIPFENDRA (enlicitide) launch progression, and 2026 revenue guidance revisions.

Industry

Receptor.AI (US Techbio) and Sethera Therapeutics Announce Monday August 3, 2026 an Integrated Discovery Alliance for AI-Guided Polymacrocyclic Peptide Medicines Combining Sethera's Proprietary Polymacrocyclic Peptide Chemistry (Installs 1-6 Stable Cross-Links to Generate Polymacrocyclic, Nested, In-Line, and Interpeptide Structures Across Large Encoded Libraries and Explores Multiple Experimentally Accessible Topologies Rather Than a Single Predetermined Structural Motif) With Receptor.AI's Physics-Based Modeling, Artificial Intelligence, and Multiparameter Optimization; The Closed-Loop Discovery and Optimization Workflow Targets Historically Hard-to-Drug Therapeutic Targets That Resist Small-Molecule and Antibody Approaches

Receptor.AI and Sethera Therapeutics announced Monday August 3, 2026 an integrated discovery alliance for AI-guided polymacrocyclic peptide medicines. Under the collaboration: Sethera generates and experimentally screens architecture-diverse polymacrocyclic peptide libraries; Receptor.AI applies physics-based modeling, artificial intelligence, and multiparameter optimization to interpret sequence, architecture, enrichment, and activity data and guide focused optimization cycles. The companies then design, synthesize, and experimentally test new candidates, feeding the resulting data into each subsequent cycle in a closed-loop discovery workflow. Sethera's platform installs 1-6 stable cross-links to generate polymacrocyclic, nested, in-line, and interpeptide structures across large encoded libraries, and (unlike constrained-peptide approaches centered on a predetermined structural motif) explores multiple experimentally accessible topologies. The collaboration targets historically hard-to-drug therapeutic targets that resist small-molecule and antibody approaches. The macrocyclic peptide modality has been commercially validated in 2026 through Merck's LIPFENDRA (enlicitide, FDA-approved July 16, 2026) as the first once-daily oral macrocyclic peptide PCSK9 inhibitor with $315/month launch pricing; Sethera and Receptor.AI aim to extend the modality to additional receptor targets.

#receptor-ai #sethera-therapeutics #polymacrocyclic-peptide #ai-drug-discovery #peptide-library-screening #cross-linked-peptides #closed-loop-workflow #hard-to-drug-targets #macrocyclic-peptide #computational-modeling
Industry

Indian Pharmaceutical Stocks Continue Monday August 3 Morning Selloff Following President Trump's Truth Social Post Confirming the Phased Generic-Drug Tariff Schedule (Zero Duty for Two Years Starting August 1 2026, Then 100% Starting August 1 2028, Then 200% Starting August 1 2029); Nifty Pharma Slumps Nearly 2% Making It the Worst-Performing Sectoral Index on the National Stock Exchange in Early Trade With Gland Pharma Leading Losses Down 4.54%, Cipla Down 1.95%, Sun Pharma Down 1.29%, and Dr Reddy's Down Similarly Given India Supplies Approximately 50% of US Generic Prescriptions by Volume

Indian pharmaceutical stocks continued the Monday August 3, 2026 morning selloff following President Trump's Truth Social post confirming the phased generic-drug tariff schedule. The Nifty Pharma index slumped nearly 2% in early trade, making it the worst-performing sectoral index on the National Stock Exchange. Individual stock movements: Gland Pharma led losses down 4.54% to Rs 2,362.5; Cipla, Sun Pharma, and Dr Reddy's Laboratories were among the top early losers at down 1.29-1.95%; Ajanta Pharma, Alkem Laboratories, Mankind Pharma, and Divi's Laboratories all traded 1.3-3% lower. Sensex fell over 400 points; Nifty slipped below 24,150. The tariff schedule: zero duty for two years starting August 1, 2026, then 100% starting August 1, 2028, then 200% starting August 1, 2029. Tariffs on patented and branded medicines (separately governed by Section 232) remain unchanged. India supplies approximately 50% of US generic prescriptions by volume (over 90% of US prescriptions overall are generics). US production costs would be 25-30% higher than in India, making the two-year transition challenging for large-scale onshoring. Analyst commentary suggests creating a viable US generic manufacturing ecosystem would take at least five years.

#indian-pharma #nifty-pharma #trump-administration #generic-tariff #gland-pharma #cipla #sun-pharma #dr-reddys #ajanta-pharma #alkem-laboratories #market-selloff
Clinical Trials

Boehringer Ingelheim Survodutide (BI 456906, Dual GLP-1/Glucagon Receptor Agonist) Phase 2 MASH (Metabolic Dysfunction-Associated Steatohepatitis) Results Continue to Circulate Ahead of Phase 3 Readouts Expected in Late 2026: 83% of MASH Patients Achieved Histological Improvement at 48 Weeks, With Phase 3 Trials for Both MASH and Obesity Underway; Survodutide Positions Boehringer to Compete Against Novo Nordisk Semaglutide (Wegovy), Eli Lilly Tirzepatide (Zepbound/Mounjaro), and the Eventual Retatrutide Triple Agonist in the Broader Cardiometabolic Space

Boehringer Ingelheim's survodutide (BI 456906) Phase 2 MASH results continue to circulate through the pharma analyst community ahead of Phase 3 readouts expected in late 2026. Survodutide is a dual GLP-1 / glucagon receptor agonist administered by once-weekly subcutaneous injection. In the Phase 2 trial in patients with biopsy-proven metabolic dysfunction-associated steatohepatitis (MASH), 83% of survodutide-treated patients achieved histological improvement at 48 weeks (versus placebo comparator). Phase 3 trials for both MASH (LIVERAGE program) and obesity (SYNCHRONIZE program) are underway. Survodutide positions Boehringer Ingelheim to compete against Novo Nordisk semaglutide (Wegovy for obesity, Ozempic for type 2 diabetes) which has approximately 15% weight loss and Rezdiffra (resmetirion) FDA-approved March 2024 for MASH; Eli Lilly tirzepatide (Zepbound for obesity, Mounjaro for type 2 diabetes) which has approximately 21% weight loss; and the eventual Eli Lilly retatrutide triple GLP-1/GIP/glucagon agonist (Phase 3 TRIUMPH program) which showed 28.3% weight loss in Phase 3 obesity readouts earlier in 2026. The dual-agonist glucagon mechanism differentiates survodutide from the pure GLP-1 and GLP-1/GIP incumbents by adding hepatic glucose output modulation and potential MASH-specific liver benefit.

#boehringer-ingelheim #survodutide #bi-456906 #glp-1-glucagon #dual-agonist #mash #metabolic-dysfunction-associated-steatohepatitis #liverage #synchronize #phase-3
Industry

Merck (NYSE: MRK) Q2 2026 Earnings Pre-Day Positioning Ahead of the Tuesday August 4 Before-Market-Open Report With Analyst Focus on Keytruda (Pembrolizumab) Sales Trajectory Ahead of the 2028 US Patent Cliff, the Initial Commercial Ramp of LIPFENDRA (Enlicitide) Oral Macrocyclic Peptide PCSK9 Inhibitor Following the July 16 FDA Approval With Peak Sales Potential of $5 Billion by 2034, Zacks Consensus of $16.33 Billion Revenue and $1.36 Diluted EPS (Down 36.2% Year-Over-Year From $2.13), and Potential 2026 Revenue Guidance Revisions From the Prior $65.8-67 Billion Range

Merck (NYSE: MRK) Q2 2026 earnings pre-day positioning ahead of the Tuesday August 4, 2026 before-market-open report. Zacks analyst consensus: $16.33 billion revenue, $1.36 diluted EPS (down 36.2% year-over-year from $2.13 in Q2 2025). Analyst focus areas: Keytruda (pembrolizumab) sales trajectory (Zacks estimate $8.06 billion Q2, driven by earlier-stage indication uptake and continued metastatic-setting momentum) ahead of the 2028 US patent cliff that ends Keytruda exclusivity; the initial commercial ramp of LIPFENDRA (enlicitide) oral macrocyclic peptide PCSK9 inhibitor following the July 16, 2026 FDA approval, with peak sales potential estimated at $5 billion by 2034 and analyst commentary describing the safety label as 'the cleanest in the class'; contribution from Winrevair (sotatercept for pulmonary arterial hypertension), Welireg (belzutifan for renal cell carcinoma), and Capvaxive (pneumococcal vaccine); and the integration of the Terns Pharmaceuticals and Cidara Therapeutics acquisitions closed in H1 2026. Merck has beaten earnings expectations in each of the trailing four quarters with a 7.75% average earnings surprise; analyst attention also on potential FY 2026 revenue guidance revision from the prior $65.8-67 billion range and non-GAAP EPS guidance from $5.04-5.16.

#merck #mrk #q2-2026-earnings #keytruda #pembrolizumab #lipfendra #enlicitide #keytruda-patent-cliff #winrevair #welireg #capvaxive #pre-earnings-positioning